<DOC>
	<DOCNO>NCT00004796</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess effect lactulose circadian rhythm plasma melatonin patient subclinical hepatic encephalopathy . II . Assess intrasubject variability circadian melatonin level neuropsychological test . III . Assess elements neuropsychological test battery show response lactulose .</brief_summary>
	<brief_title>Phase II Study Lactulose Circadian Rhythms Patients With Cirrhosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients alternately assign 1 2 treatment group : therapy 3 week follow lactulose 3 week versus lactulose 3 week follow therapy 3 week . A dietician advise patient 1 g/kg per day protein diet . The lactulose dose adjust result 2 3 loose bowel movement per day .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Clinical diagnosis cirrhosis portal hypertension portalsystemic shunt Prior/Concurrent Therapy No concurrent therapy hepatic encephalopathy Patient Characteristics Age : Under 65 Performance status : Not specify Hematopoietic : Not specify Hepatic : See Disease Characteristics Renal : Not specify Other : No alcohol intake within 1 month prior entry No requirement beta blocker No requirement corticosteroids Not intercontinental travel</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 1998</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>hypertensive disorder</keyword>
	<keyword>portal hypertension</keyword>
	<keyword>rare disease</keyword>
</DOC>